8-K: Avadel Acquisition Court Hearing Set for February 10

The High Court of Ireland has scheduled a hearing for February 10, 2026, to sanction the proposed acquisition of Avadel Pharmaceuticals by Alkermes plc.

Summary

• The High Court of Ireland has set a Sanction Court Hearing for February 10, 2026, at 11:00 a.m. (Irish time).
• The hearing will consider Avadel Pharmaceuticals plc's application to sanction the proposed scheme of arrangement for Alkermes plc to acquire Avadel's entire issued and to be issued ordinary share capital.
• Interested parties intending to appear at the Sanction Court Hearing must notify Avadel's solicitors, Arthur Cox LLP, in writing by no later than 5:30 p.m. (Irish time) on February 5, 2026.
• Such notification must indicate whether the party intends to support or oppose the application.
• Any affidavit in support of an appearance must be filed with the Central Office of the High Court of Ireland and served on Avadel's solicitors by no later than 5:30 p.m. (Irish time) on February 5, 2026.
• The Acquisition is expected to close shortly after the Court issues an order sanctioning the Scheme.

Sentiment

Score: 6

Explanation: The filing indicates positive progress towards the completion of an acquisition, which provides certainty for shareholders, but also includes standard cautionary statements regarding potential risks and delays inherent in such transactions.

Positives

• The acquisition process is progressing with a specific court hearing scheduled.
• The acquisition is expected to close shortly after the Court issues an order sanctioning the Scheme, indicating a clear path to completion.

Risks

• The ability of the parties to consummate the Acquisition in a timely manner or at all.
• The satisfaction (or waiver) of conditions to the consummation of the Acquisition.
• Potential delays in consummating the Acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the Acquisition.
• The impact of health pandemics on the parties' respective businesses and the actions the parties may take in response thereto.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the transaction agreement.
• The effect of the announcement or pendency of the Acquisition on Avadel's business relationships, operating results and business generally.
• Costs related to the Acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the Acquisition.

Future Outlook

The Acquisition is expected to close shortly after the High Court of Ireland issues an order sanctioning the Scheme of arrangement.

Management Comments

• The directors of Avadel accept responsibility for the information contained in this report.
• To the best of the knowledge and belief of the directors of Avadel (who have taken all reasonable care to ensure such is the case), the information contained in this report is in accordance with the facts and does not omit anything likely to affect the import of such information.

Industry Context

This announcement is a specific corporate action related to the merger and acquisition landscape within the pharmaceutical sector, indicating consolidation activity.

Legal Proceedings

• A Sanction Court Hearing is scheduled for February 10, 2026, in the High Court of Ireland to consider the application to sanction the scheme of arrangement for the acquisition.
• The filing mentions a risk of 'the outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the transaction agreement or the Acquisition'.

Stakeholder Impact

• Shareholders: The acquisition involves the entire issued and to be issued ordinary share capital of Avadel.
• Interested parties: Have the opportunity to appear at the Sanction Court Hearing and express support or opposition to the scheme of arrangement.
• Directors: Accept responsibility for the information provided in the report.

Next Steps

• Interested parties must notify Avadel's solicitors by February 5, 2026, if they intend to appear at the Sanction Court Hearing.
• The Sanction Court Hearing will take place on February 10, 2026.
• The Acquisition is expected to close shortly after the Court issues an order sanctioning the Scheme.

Key Dates

Recommendation

This filing provides a procedural update on an ongoing acquisition, confirming that the process is moving forward with a scheduled court hearing. While this reduces uncertainty regarding the deal's progression, it does not introduce new financial performance data or alter the fundamental valuation thesis for Avadel, which is largely tied to the acquisition terms. Investors are likely awaiting the final court sanction and deal closure. Therefore, a 'hold' recommendation is appropriate for those positioned for the acquisition, as this update confirms the path without providing new catalysts for buying or selling based on operational performance.

Keywords

Avadel Pharmaceuticals, Alkermes, acquisition, merger, scheme of arrangement, Ireland, High Court, pharmaceuticals, AVDL